ROS1-positive non-small cell lung cancer, a rare subtype of lung cancer, involves a mutation that therapies — some of which have been recently approved by the Food and Drug Administration — can target ...

Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.

Dr. Maurie Markman comments on a study in Lancet Oncology indicating that patients with NSCLC patients who have an EGFR mutation benefit more from gefitinib than from cisplatin/docetaxel.

Then the samples detected SNV candidate mutations. Finally, the frequency distribution of the candidate SNV loci was calculated. HPF-SNP consists of two parts, Germ_Control_Set is for filter germline ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

But tumor-only analyses offer up many “false positive” mutations that appear to contribute to cancer, but which actually show up elsewhere in an individual’s healthy tissue, a new study finds.

The researchers identified the various mutations that have crept into the bacteria gene pool, and then they tried to figure out which combinations of mutations had the most positive effect. They ...

The SACHI Phase III study evaluates savolitinib and osimertinib for EGFR mutation-positive NSCLC patients after EGFR inhibitor therapy. What were the key results of the SACHI study?

Association of germline homologous recombination deficiency mutations with HER2 status conversion from negative to positive following neoadjuvant chemotherapy in breast cancer.

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a Phase III clinical trial ...